What is the grading and treatment approach for retinopathy of prematurity (ROP) in a premature infant with low birth weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Retinopathy of Prematurity Grading and Treatment

ROP is classified by location (zone I-III), stage (1-5), extent (clock hours), and presence of plus disease, with treatment indicated for type 1 ROP using laser photocoagulation as the gold standard, particularly for zone II disease. 1, 2

ROP Classification System

Anatomic Zones

  • Zone I: Central retina around the optic disc—highest risk area for severe disease 1
  • Zone II: Extends from zone I to the nasal ora serrata—most common location for treatable ROP 2
  • Zone III: Residual temporal crescent—lowest risk, rarely requires treatment 1, 2

Disease Stages

  • Stage 1: Demarcation line separating vascular from avascular retina 3
  • Stage 2: Ridge formation with height and width 3
  • Stage 3: Extraretinal fibrovascular proliferation on the ridge 3
  • Stage 4: Partial retinal detachment 4
  • Stage 5: Total retinal detachment 4

Plus Disease

Plus disease indicates vascular dilation and tortuosity in the posterior pole, signifying increased severity and need for closer monitoring or treatment 3, 4

Treatment Thresholds

Type 1 ROP (Treatment Required)

Immediate treatment is indicated for type 1 ROP to prevent blindness: 2, 5

  • Zone I: Any stage with plus disease
  • Zone I: Stage 3 without plus disease
  • Zone II: Stage 2 or 3 with plus disease

Type 2 ROP (Close Observation)

These infants require ophthalmology visits every 1-2 weeks but do not require immediate treatment: 1, 2

  • Zone I: Stage 1 or 2 without plus disease
  • Zone II: Stage 3 without plus disease

Treatment Modalities

Primary Treatment: Laser Photocoagulation

Peripheral laser ablation remains the gold standard treatment, particularly for zone II disease, as it has proven effective in reducing blindness from ROP. 6, 2, 7

Alternative/Adjunctive: Anti-VEGF Therapy

Anti-VEGF agents (bevacizumab, ranibizumab) may be used as monotherapy or combined with laser, especially for zone I disease 7. However, laser photocoagulation should be prioritized as the established standard 7.

Surgical Intervention

Surgery is reserved for advanced stages (stage 4-5) with retinal detachment 3, 7

Critical Management Considerations

Oxygen Management

  • Target oxygen saturation of 96-99% does not increase ROP progression risk in infants with pre-threshold disease 6, 1
  • Once past the age of oxygen-induced retinopathy risk, target saturation of 95% or higher is recommended 2
  • Avoid sustained hyperoxemia in infants with peripheral avascular retina 6

Follow-up Protocol

For infants with zone I or II disease: 1, 2

  • Schedule ophthalmology visits every 1-2 weeks depending on severity
  • Missing follow-up appointments can result in preventable blindness 6, 2

Screening can be discontinued when: 1, 2

  • ROP is regressing with vessels passed into zone III on at least two sequential examinations
  • Complete retinal vascularization is achieved
  • Stage 0 zone III disease is present

Special Populations

Infants with chronic lung disease require heightened vigilance: 1, 2

  • Screen even if between 29-37 weeks gestation
  • Careful coordination of follow-up appointments is crucial when discharged home
  • Parents cannot usually provide close oxygen control without extensive support 6

Screening Guidelines

Who to Screen

Screen all infants with: 1

  • Less than 32 weeks gestational age at birth (conservative approach)
  • Birth weight less than 1251 g (98.1% of type 1 or 2 ROP occurs in this group) 5
  • 29-37 weeks gestation with unstable course requiring supplemental oxygen 1

Timing of First Examination

Perform initial screening at the later of: 1

  • 31-33 weeks postmenstrual age, OR
  • 4 weeks chronological age

Examination Requirements

The examination must be conducted by an ophthalmologist experienced in evaluating ROP in premature infants using indirect ophthalmoscopy with adequate dilation. 1 Telemedicine approaches with wide-field digital retinal imaging are acceptable when coupled with timely referral pathways 1.

Common Pitfalls to Avoid

  • Never discharge infants with zone I or II disease without confirmed follow-up appointments—this is the greatest risk for preventable blindness 6, 1
  • Do not assume medically stable infants between 29-37 weeks are safe from ROP if they have chronic lung disease 1
  • Avoid restricting oxygen excessively in infants with pre-threshold ROP, as saturations of 96-99% are safe 6
  • Only about 49.4% of eyes are vascularized into zone III by 37 weeks postmenstrual age, so do not discontinue screening prematurely 5

References

Guideline

Timing of First ROP Screening Examination in Newborns

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment and Management of Retinopathy of Prematurity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

An Update on Retinopathy of Prematurity (ROP).

Indian journal of pediatrics, 2017

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Update in the Treatment of Retinopathy of Prematurity.

American journal of perinatology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.